Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GKL-006 Injection in Unresectable Hepatocellular Carcinoma
NCT07713290Phase 1Active, not recruiting
- Sponsor
- GenePlus
- Start
- Apr 2025
- Primary completion
- Nov 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GKL-006 in hepatocellular carcinoma (HCC), sponsored by GenePlus. Primary endpoint: Incidence and Severity of Treatment-Related Adverse Events and Safety/Tolerability Risks. Started Apr 2025; status: active, not recruiting.
02
Drugs
GKL-006
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07713290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07713290.